Pathogenic Mechanism of Spinocerebellar Ataxia Type 10
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10
批准号:
7225179
负责人:
TETSUO ASHIZAWA
金额:
$32.99万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2010-03-31
关键词:
22q13.33&apos Untranslated RegionsAge-MonthsAmino Acid SequenceArtsAtaxiaBacterial Artificial ChromosomesBehavioralBindingBinding ProteinsBrainCDKN1A geneCardiacCell physiologyCellsCerebellar AtaxiaChromosomesCollaborationsCompatibleCultured CellsDNADataDevelopmentDiseaseDisruptionEmbryoEndoribonucleasesEpilepsyExhibitsFoundationsFunctional disorderFundingFutureGenesGeneticGenomicsGenotypeGlycine ReceptorsGoalsHereditary DiseaseHeterogeneous-Nuclear Ribonucleoprotein KHeterogeneous-Nuclear RibonucleoproteinsHomologous GeneHumanIn VitroIntronsKnowledgeLeadLibrariesLocalizedMediatingMessenger RNAModelingMolecularMolecular BiologyMouse, Founder, TransgenicMusMutationNeuronal DifferentiationNeuronsNorthern BlottingNuclearPancreatic ribonucleasePatientsPediatric HospitalsPentanucleotide RepeatsPeptide Sequence DeterminationPhenotypePlayPolyadenylationPolypyrimidine Tract-Binding ProteinPrionsProcessProtein BindingProteinsProteomicsPublishingRNARNA ProcessingRNA SplicingReagentReporterResearch PersonnelRetroviral VectorRibonucleasesRoleSamplingSpinocerebellar AtaxiasTechnologyTestingTherapeuticTranscriptTransgenic MiceTransgenic OrganismsTranslatingTranslationsTroponin TWorkbasedisease phenotypeexperiencegain of functionhuman diseaseinnovationlead-binding proteinsloss of functionmouse modelmutantoncoprotein p21paralogous geneprogramspromoterresearch studysize
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Spinocerebellar ataxia type 10 (SCA10) is an autosomal dominant disorder characterized by ataxia, epilepsy and anticipation. A large expansion of the ATTCT repeat in intron 9 of the SCA10 gene encoding the E46L protein is the mutation responsible for this disease. The mechanism by which the expansion mutation leads to the disease phenotype is unknown. The goal of this project is to elucidate the pathogenic mechanism of SCA10. The long-term goal is to develop a rational therapy for SCA10 based on the pathogenic mechanism. The central hypothesis is that the major pathogenic mechanism of SCA10 is due to the disruption of the normal cellular function of polyprimidine tract binding proteins (PTBs) by the large expanded AUUCU repeat in the E46L RNA. This hypothesis is based on preliminary data that (i) SCA10 cells do not show altered levels of E46L mRNA and protein, (ii) loss of function of the E46L protein does not lead to a SCA10-like phenotype in mice, (iii), expanded ATTCT repeats are transcribed and accumulated in nuclear foci, and (iv) 3 species of PTBs (PTB, nPTB and hnRNP K) bind to AUUCU repeats in vitro and at least 1 (hnRNP K) co-localizes in the nuclear foci in cells derived from an SCA10 patient. The following 2 Specific Aims will be used to test our hypothesis. Specific Aim 1 is to demonstrate that the transcript with an expanded AUUCU repeat gains toxic functions by binding and perturbing the function of PTBs in SCA10 cells. It is expected that (a) there is a detectable level of the expanded AUUCU repeat in SCA10 cells, and (b) expanded AUUCU repeats in SCA10 cells bind to PTBs and alter the cellular functions of PTBs. Specific Aim 2 is to establish genetic mouse models of SCA10. Aim 2 will be accomplished by (a) identifying the SCA10-like phenotype in the transgenic mice that express expanded AUUCU repeats, and (b) establishing genetic mouse models of SCA10 that lack the Hnrpk gene encoding hnRNP K and the Ptbp2 gene encoding the brain-specific nPTB. Transgenic mice expressing expanded AUUCU repeats are expected to exhibit an SCA10-like phenotype by the RNA-mediated gain of function through deficiency of these PTBs. Elucidating the disease mechanism of SCA10 is innovative because SCA10 is the only human disease known to be caused by an expansion of a pentanucleotide repeat. Establishing the mechanism in SCA10 will fill the current gap of knowledge and facilitate the development of rational therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Supplementary funding for U01NS104326 Clinical Trial Readiness for SCA1 and SCA3 (“READISCA”)
-
批准号:10623060
-
项目类别:
-
资助金额:$16.38万
-
财政年份:2022
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Genetic mechanism of conserved ancestral haplotype in SCA10
-
批准号:9890198
-
项目类别:
-
资助金额:$15.91万
-
财政年份:2019
-
负责人:TETSUO ASHIZAWA
-
依托单位:
The 1st SCA Global Conference
-
批准号:9763231
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2019
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Genetic mechanism of conserved ancestral haplotype in SCA10
-
批准号:10545044
-
项目类别:
-
资助金额:$15.91万
-
财政年份:2019
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Genetic mechanism of conserved ancestral haplotype in SCA10
-
批准号:10093170
-
项目类别:
-
资助金额:$15.91万
-
财政年份:2019
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Clinical Trial Readiness for SCA1 and SCA3
-
批准号:10091534
-
项目类别:
-
资助金额:$122.05万
-
财政年份:2018
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Clinical Trial Readiness for SCA1 and SCA3
-
批准号:9438347
-
项目类别:
-
资助金额:$126.09万
-
财政年份:2018
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Clinical Trial Readiness for SCA1 and SCA3
-
批准号:10327685
-
项目类别:
-
资助金额:$109.88万
-
财政年份:2018
-
负责人:TETSUO ASHIZAWA
-
依托单位:
RNA-Gain-of-Function Pathogenesis in SCA10
-
批准号:8557439
-
项目类别:
-
资助金额:$32.32万
-
财政年份:2013
-
负责人:TETSUO ASHIZAWA
-
依托单位:
RNA-Gain-of-Function Pathogenesis in SCA10
-
批准号:8793081
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2013
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Clinical Research Consortium for Spinocerebellar Ataxias
-
批准号:7839369
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Clinical Research Consortium for Spinocerebellar Ataxias
-
批准号:7940980
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10
-
批准号:7576918
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2006
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10
-
批准号:7391093
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2006
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10
-
批准号:7103348
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2006
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Spinocerebellar Ataxia Type 10
-
批准号:6322240
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2001
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Spinocerebellar Ataxia Type 10
-
批准号:6540440
-
项目类别:
-
资助金额:$1.64万
-
财政年份:2001
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Spinocerebellar Ataxia Type 10
-
批准号:6679655
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2001
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Spinocerebellar Ataxia Type 10
-
批准号:6770106
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2001
-
负责人:TETSUO ASHIZAWA
-
依托单位:
Spinocerebellar Ataxia Type 10
-
批准号:6639764
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2001
-
负责人:TETSUO ASHIZAWA
-
依托单位:
国内基金
登录
查看更多内容
3'-甲氧基葛根素生物合成途径中关键甲基转移酶基因的克隆与功能分析
-
批准号:31300258
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:黎佳
-
依托单位:
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
-
批准号:81300507
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2013
-
负责人:陈黎
-
依托单位:
3'-UTR单核苷酸多态性影响CYP8B1基因表达致胆囊胆固醇结石形成的机制研究
-
批准号:81370561
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:秦俭
-
依托单位:
异源杂交多倍化鲫鲤特有性状的转录组及后转录组水平变化规律研究
-
批准号:31360514
-
项目类别:地区科学基金项目
-
资助金额:54.0万元
-
批准年份:2013
-
负责人:罗静
-
依托单位:
HIF基因3'UTR区SNP参与胰腺癌HIF-1α表达调控的分子机制及功能研究
-
批准号:81302082
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王秀超
-
依托单位:
鼻咽癌转移相关通路分子的microRNA调控机制及3'UTR区可变剪切的作用研究
-
批准号:81372886
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:买世娟
-
依托单位:
小鼠精原干细胞中APA位点研究及3'UTR使用频率数据库构建
-
批准号:31301085
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2013
-
负责人:熊远妍
-
依托单位: